Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review
Robert J. Nordyke, Tyler D. Wagner, Janine Ross, Sreeranjani Menon, Jonathan D. Campbell · 2026
Read Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review by Robert J. Nordyke, Tyler D. Wagner, Janine Ross, Sreeranjani Menon, Jonathan D. Campbell (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13687151.txt.
Description
Robert Nordyke and co-authors review how much of the social gain from new drugs goes to drug makers, in a 2026 paper. Drug pricing rests on a balance: reward firms for future work while keeping current drugs within reach. The maker's share of total gain is a key gauge of that balance.
The review gathered twenty four studies with sixty eight estimates of that share. Estimates ranged from near zero to well over one hundred percent, with a middle value near fifteen percent. Gaps came mostly from disease traits and unlike methods. Most studies missed parts of the social gain or mixed maker revenue with wider supply chain gains.
Catalog record
| CREATOR | Robert J. Nordyke, Tyler D. Wagner, Janine Ross, Sreeranjani Menon, Jonathan D. Campbell |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |